Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, Nagler A, Peled A (2007) Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 25(9):2158–2166

Article  CAS  PubMed  Google Scholar 

Abraham M, Klein S, Bulvik B, Wald H, Weiss ID, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, Galun E, Avigdor A, Benjamini O, Nagler A, Pereg Y, Tavor S, Peled A (2017) The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. Leukemia 31(11):2336–2346

Article  CAS  PubMed  Google Scholar 

Afshar-Khamseh R, Javeri A, Taha MF (2021) MiR-146a suppresses the expression of CXCR4 and alters survival, proliferation and migration rate in colorectal cancer cells. Tissue Cell 73:101654

Article  CAS  PubMed  Google Scholar 

Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H (2008) Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci 99(3):539–542

Article  CAS  PubMed  Google Scholar 

Alghasi A, Farnoosh G, Boroujeni AS, Bahadoram M, Gandomkari ST, Mahmoudian-Sani M-R (2021) Single nucleotide polymorphisms associated with gastric cancer in Iranian patients. Immunopathol Persa 7(2):6

Article  Google Scholar 

Aliyari-Serej Z, Ebrahimi A, Kazemi T, Najafi S, Roshani E, Ebrahimi-Kalan M, Baradaran B (2020) Relation between Immune cell response and stemness genes expression in breast cancer; a new approach in NANOG gene and Let7-a expression in breast cancer cell lines. Immunopathol Persa 6(2):e21–e21

Article  Google Scholar 

Ameen F, Al-Maary KS, Almansob A, AlNadhari S (2022) Antioxidant, antibacterial and anticancer efficacy of Alternaria chlamydospora-mediated gold nanoparticles. Appl Nanosci 1–8

Amri A, Soltanian AR, Borzouei S (2022) Survival rates and prognostic factors of thyroid cancer: a retrospective cohort study. J Parathyr Dis 10:e11162

Article  Google Scholar 

Andritsos LA, Byrd JC, Cheverton P, Wu J, Sivina M, Kipps TJ, Burger JA (2019) A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leuk Lymphoma 60(14):3461–3469

Article  CAS  PubMed  Google Scholar 

Andtbacka R, Pierce RH, Campbell JS, Yushak M, Milhem M, Ross MI, Grossmann KF, Sprott K, Tsiroyannis E, Niland K (2018) X4P–001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma. Cancer Res 400:200

Google Scholar 

Aravindan S, Ramraj S, Kandasamy K, Thirugnanasambandan SS, Somasundaram DB, Herman TS, Aravindan N (2017) Hormophysa triquerta polyphenol, an elixir that deters CXCR4-and COX2-dependent dissemination destiny of treatment-resistant pancreatic cancer cells. Oncotarget 8(4):5717

Article  PubMed  Google Scholar 

Ardalan M (2016) Parathyroid carcinoma; an updated mini-review on current trends. J Parathyr Dis 4(2):57–59

Google Scholar 

Arnolds KL, Spencer JV (2014) CXCR4: a virus’s best friend? Infect Genet Evol 25:146–156

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bachelder RE, Wendt MA, Mercurio AM (2002) Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62(24):7203–7206

CAS  PubMed  Google Scholar 

Balkwill F (2004a) Cancer and the chemokine network. Nat Rev Cancer 4(7):540–550

Article  CAS  PubMed  Google Scholar 

Balkwill F (2004b) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14(3):171–179

Article  CAS  PubMed  Google Scholar 

Baral S, Pariyar R, Kim J, Lee HS, Seo J (2017) Quercetin-3-O-glucuronide promotes the proliferation and migration of neural stem cells. Neurobiol Aging 52:39–52

Article  CAS  PubMed  Google Scholar 

Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL, Zona GL, Spaziante R, Florio T, Schettini G (2003) Stromal cell-derived factor 1α stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Can Res 63(8):1969–1974

CAS  Google Scholar 

Barbieri F, Bajetto A, Thellung S, Wurth R, Florio T (2016) Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma. Expert Opin Drug Discov 11(11):1093–1109

Article  CAS  PubMed  Google Scholar 

Bartolomé RA, Ferreiro S, Miquilena-Colina ME, Martínez-Prats L, Soto-Montenegro ML, García-Bernal D, Vaquero JJ, Agami R, Delgado R, Desco M (2009) The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol 174(2):602–612

Article  PubMed  PubMed Central  Google Scholar 

Becker PS, Foran JM, Altman JK, Yacoub A, Castro JE, Sabbatini P, Dilea C, Wade M, Xing G, Gutierrez A (2014) Targeting the CXCR4 pathway: safety, tolerability and clinical activity of ulocuplumab (BMS-936564), an anti-CXCR4 antibody, in relapsed/refractory acute myeloid leukemia. Blood 124(21):386

Article  Google Scholar 

Beider K, Begin M, Abraham M, Wald H, Weiss ID, Wald O, Pikarsky E, Zeira E, Eizenberg O, Galun E, Hardan I, Engelhard D, Nagler A, Peled A (2011) CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol 39(3):282–292

Article  CAS  PubMed  Google Scholar 

Beider K, Ribakovsky E, Abraham M, Wald H, Weiss L, Rosenberg E, Galun E, Avigdor A, Eizenberg O, Peled A, Nagler A (2013) Targeting the CD20 and CXCR4 pathways in non-Hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140. Clin Cancer Res 19(13):3495–3507

Article  CAS  PubMed  Google Scholar 

Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, Wald O, Galun E, Eizenberg O, Peled A, Nagler A (2014) Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther 13(5):1155–1169

Article  CAS  PubMed  Google Scholar 

Berning P, Schaefer C, Clemens D, Korsching E, Dirksen U, Potratz J (2018) The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling. Cell Commun Signal 16(1):21

Article  PubMed  PubMed Central  Google Scholar 

Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, Gopinathan A, Isherwood C, Gallagher FA, Pawula M, Hudecova I, Gale D, Rosenfeld N, Barmpounakis P, Popa EC, Brais R, Godfrey E, Mir F, Richards FM, Fearon DT, Janowitz T, Jodrell DI (2020) CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci USA 117(46):28960–28970

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bobkov V, Zarca AM, Van Hout A, Arimont M, Doijen J, Bialkowska M, Toffoli E, Klarenbeek A, van der Woning B, van der Vliet HJ, Van Loy T, de Haard H, Schols D, Heukers R, Smit MJ (2018) Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions. Biochem Pharmacol 158:413–424

Article  CAS  PubMed  Google Scholar 

Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M (2018) Initial report of a phase I study of LY2510924, idarubicin, and cytarabine in relapsed/refractory acute myeloid leukemia. Front Oncol 8:369

Article  PubMed  PubMed Central  Google Scholar 

Borthakur G, Tallman M, Ofran Y, Foran J, Uy G, DiPersio J, Nagler A, Rowe J, Showel M, Altman J (2018) The CXCR4 inhibitor BL-8040 in combination with cytarabine results in a significantly extended overall survival of relapsed/refractory AML patients. EHA Libr 215317:S993

Google Scholar 

Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R (2010) FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 78(3–4):282–288

Article  CAS  PubMed  Google Scholar 

Broussas M, Boute N, Akla B, Berger S, Beau-Larvor C, Champion T, Robert A, Beck A, Haeuw J-F, Goetsch L (2016) A new anti-CXCR4 antibody that blocks the CXCR4/SDF-1 axis and mobilizes effector cells. Mol Cancer Ther 15(8):1890–1899

Article  CAS  PubMed  Google Scholar 

Burger JA, Burkle A (2007) The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 137(4):288–296

Article  CAS  PubMed  Google Scholar 

Burger JA, Peled A (2009) CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23(1):43–52

Article  CAS  PubMed  Google Scholar 

Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106(5):1824–1830

Article  CAS  PubMed  Google Scholar 

Burger JA, Stewart DJ, Wald O, Peled A (2011) Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther 11(4):621–630

Article  CAS  PubMed  Google Scholar 

Busillo JM, Benovic JL (2007) Regulation of CXCR4 signaling. Biochim Biophys Acta 1768(4):952–963

Article  CAS  PubMed  Google Scholar 

Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL (2010) Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem 285(10):7805–7817

Article  CAS  PubMed